Thanks TechGuru, I would tend to agree that it
Post# of 150907
(Total Views: 577)
Posted On: 09/07/2022 6:34:24 AM
Thanks TechGuru,
I would tend to agree that it is low hanging fruit and that we should pursue it aggressively.
However, it lies #4 on the Priority list:
1) Lift the Clinical Hold
2) NASH
3) NASH & HIV
4) mTNBC and mColon Cancer, Basket Tumors
Certainly, I believe we have NDAs on all these indications.
Given the order of priorities, it may be that the NDAs on #2 and #3 are just a bit more promising and set in stone than the NDAs for #4.
Just a thought.
I would tend to agree that it is low hanging fruit and that we should pursue it aggressively.
However, it lies #4 on the Priority list:
1) Lift the Clinical Hold
2) NASH
3) NASH & HIV
4) mTNBC and mColon Cancer, Basket Tumors
Certainly, I believe we have NDAs on all these indications.
Given the order of priorities, it may be that the NDAs on #2 and #3 are just a bit more promising and set in stone than the NDAs for #4.
Just a thought.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼